CA2381123C - Complexes et conjugat d'actinium-225 pour radio-immunotherapie - Google Patents
Complexes et conjugat d'actinium-225 pour radio-immunotherapie Download PDFInfo
- Publication number
- CA2381123C CA2381123C CA2381123A CA2381123A CA2381123C CA 2381123 C CA2381123 C CA 2381123C CA 2381123 A CA2381123 A CA 2381123A CA 2381123 A CA2381123 A CA 2381123A CA 2381123 C CA2381123 C CA 2381123C
- Authority
- CA
- Canada
- Prior art keywords
- hydrogen
- independently
- group
- proviso
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011363 radioimmunotherapy Methods 0.000 title abstract description 5
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical class [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 title abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 118
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 118
- 229940125666 actinium-225 Drugs 0.000 claims abstract description 91
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 43
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 20
- 125000005647 linker group Chemical group 0.000 claims abstract description 13
- 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 claims abstract description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 9
- 239000012634 fragment Substances 0.000 claims abstract description 9
- 125000006850 spacer group Chemical group 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 230000000269 nucleophilic effect Effects 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 239000002243 precursor Substances 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- -1 nitro, amino, isothiocyanato, semicarbazido, thiosemicarbazido, carboxyl Chemical group 0.000 claims description 58
- 239000013522 chelant Substances 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
- FMRNBUOIIAEPTN-UHFFFAOYSA-N 10-[carboxy-(5-isothiocyanato-2-methoxyphenyl)methyl]-9-methyl-1,4,7,10-tetrazacyclododecane-1,4,7-tricarboxylic acid Chemical compound COC1=CC=C(N=C=S)C=C1C(C(O)=O)N1C(C)CN(C(O)=O)CCN(C(O)=O)CCN(C(O)=O)CC1 FMRNBUOIIAEPTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 23
- 239000000203 mixture Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229960001484 edetic acid Drugs 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 229940120146 EDTMP Drugs 0.000 description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940127121 immunoconjugate Drugs 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229960003330 pentetic acid Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OLOMBAYFBVCLCE-UHFFFAOYSA-N 2-[1,2,5,11,14-pentakis(carboxymethyl)-1,2,5,8,11,14-hexazacyclohexadec-8-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)N(CC(O)=O)CCN(CC(O)=O)CC1 OLOMBAYFBVCLCE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HKFKNKJQPIZCIO-UHFFFAOYSA-N 2-[4,7,10,13-tetrakis(carboxymethyl)-1,4,7,10,13-pentazacyclopentadec-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 HKFKNKJQPIZCIO-UHFFFAOYSA-N 0.000 description 1
- GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 description 1
- AQWXHYUWFUXFFH-UHFFFAOYSA-N 3-[4,7,10-tris(2-carboxyethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCN(CCC(O)=O)CCN(CCC(O)=O)CCN(CCC(O)=O)CC1 AQWXHYUWFUXFFH-UHFFFAOYSA-N 0.000 description 1
- SOUJYUTZZAWCOV-UHFFFAOYSA-N 3-[4,8,11-tris(2-carboxyethyl)-1,4,8,11-tetrazacyclotetradec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCCN(CCC(O)=O)CCN(CCC(O)=O)CCCN(CCC(O)=O)CC1 SOUJYUTZZAWCOV-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101710130081 Aspergillopepsin-1 Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940051022 radioimmunoconjugate Drugs 0.000 description 1
- 230000001950 radioprotection Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- MRYQZMHVZZSQRT-UHFFFAOYSA-M tetramethylazanium;acetate Chemical compound CC([O-])=O.C[N+](C)(C)C MRYQZMHVZZSQRT-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Cette invention a trait à des complexes d'actinium-225 (?225¿Ac) possédant des chelatants fonctionnalisés correspondant à la formule (I). Dans cette formule, chaque Q représente, de manière indépendante, un hydrogène ou (CHR?5¿)¿p?CO¿2?R, Q?1¿ représente un hydrogène ou (CHR?5¿)¿w?CO¿2?R, chaque R représente, de manière indépendante, un hydrogène, un benzyle ou un alkyle porteur de 1 à 4 atomes de carbone, à la condition qu'au moins deux éléments formés par la somme de Q et de Q?1¿ représentent un autre atome que celui de l'hydrogène, chaque R?5¿ représente, de manière indépendante un hydrogène, un alkyle porteur de 1 à 4 atomes de carbone ou un (C¿1?-C¿2? alkyl)phényle, X et Y représentent, chacun de manière indépendante, un hydrogène ou peuvent, pris avec un X et un Y adjacents, former une liaison supplémentaire carbone-carbone, la valeur de n est 0 ou 1, m représente un nombre entier dont la valeur est comprise entre 0 et 10 inclus, la valeur de p est 1 ou 2, celle de r est 0 ou 1, celle de w est 0 ou 1, à la condition que la valeur de n ne soit que 1 lorsque X et/ou Y constituent une liaison supplémentaire carbone-carbone et que la somme de r et de w s'échelonne entre 0 et 1, L représente un groupe lieur/séparateur lié de façon covalente à un atome d'hydrogène de l'un des atomes de carbone auquel il est relié et remplace celui-ci, ce groupe lieur/séparateur correspondant à la formule (1), dans laquelle S représente un nombre entier d'une valeur s'échelonnant de 0 à 1, t représente un nombre entier d'une valeur s'échelonnant de 0 à 20 inclus, R?1¿ représente un fragment électrophile ou nucléophile permettant un rattachement covalent à un anticorps ou à un fragment de celui-ci ou bien un lieur de synthèse pouvant être rattaché à un anticorps ou à un fragment ou à un précurseur de celui-ci, Cyc représente un fragment aliphatique cyclique, un fragment aromatique, un fragment aliphatique hétérocyclique ou un fragment aromatique hétérocyclique, chacun desdits fragments étant éventuellement substitués par un ou plusieurs groupes n'interférant pas avec la liaison à un anticorps ou à un fragment d'anticorps, à la condition que, lorsque la valeur de s, t, m, r, et de n est 0, R?1¿ représente autre chose qu'un carboxyle. Cette invention, qui porte également sur les sels acceptables du point de vue pharmaceutique, ainsi que sur les conjugats de ces complexes, concerne, de surcroît, l'utilisation qui en est faite en matière de radio-immunothérapie.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18522000P | 2000-02-25 | 2000-02-25 | |
US60/185,220 | 2000-02-25 | ||
PCT/US2001/005927 WO2001066155A2 (fr) | 2000-02-25 | 2001-02-23 | Complexes et conjugat d'actinium-225 pour radio-immunotherapie |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2381123A1 CA2381123A1 (fr) | 2001-09-13 |
CA2381123C true CA2381123C (fr) | 2011-10-04 |
Family
ID=22680097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2381123A Expired - Lifetime CA2381123C (fr) | 2000-02-25 | 2001-02-23 | Complexes et conjugat d'actinium-225 pour radio-immunotherapie |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1227849A2 (fr) |
AU (1) | AU4906901A (fr) |
CA (1) | CA2381123C (fr) |
HU (1) | HUP0203743A2 (fr) |
WO (1) | WO2001066155A2 (fr) |
ZA (1) | ZA200200659B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
AU1123202A (en) * | 2000-09-15 | 2002-03-26 | Sloan Kettering Inst Cancer | Targeted alpha particle therapy using actinium-225 conjugates |
US6670456B2 (en) | 2001-02-28 | 2003-12-30 | Dow Global Technologies Inc. | Actinium-225 complexes and conjugates for targeted radiotherapy |
GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
NZ606996A (en) * | 2003-04-15 | 2014-08-29 | Algeta As | Thorium-227 for use in radiotherapy of soft tissue disease |
GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
EP3142710A4 (fr) * | 2014-05-16 | 2018-04-25 | Memorial Sloan Kettering Cancer Center | Marquage en une étape par actinium-225 d'anticorps pour obtenir une haute activité spécifique |
CA3121553A1 (fr) * | 2018-11-30 | 2020-06-04 | Actinium Pharmaceuticals, Inc. | Anticorps conjugues a l'actinium 225 et l'actinium 227, compositions et procedes associes |
CN111808161A (zh) * | 2020-06-01 | 2020-10-23 | 北京大学 | 一种对生物化合物进行放射性标记的方法 |
WO2022006269A1 (fr) * | 2020-06-30 | 2022-01-06 | The Johns Hopkins University | Combinaison non intuitive de supports d'administration médicamenteuse du même médicament pour retarder la croissance synergique de tumeurs solides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0720989B2 (ja) * | 1988-05-25 | 1995-03-08 | アメリカ合衆国 | 大環状キレート化合物の抱合体と診断的テスト方法 |
US6120768A (en) * | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
WO2000059896A1 (fr) * | 1999-03-23 | 2000-10-12 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | 225ac-heha et composes, procedes de synthese et procedes d'utilisation correspondants |
NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
-
2001
- 2001-02-23 HU HU0203743A patent/HUP0203743A2/hu unknown
- 2001-02-23 CA CA2381123A patent/CA2381123C/fr not_active Expired - Lifetime
- 2001-02-23 AU AU49069/01A patent/AU4906901A/en not_active Abandoned
- 2001-02-23 EP EP01922246A patent/EP1227849A2/fr not_active Withdrawn
- 2001-02-23 WO PCT/US2001/005927 patent/WO2001066155A2/fr not_active Application Discontinuation
-
2002
- 2002-01-23 ZA ZA200200659A patent/ZA200200659B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200200659B (en) | 2003-01-23 |
CA2381123A1 (fr) | 2001-09-13 |
WO2001066155A8 (fr) | 2002-02-07 |
EP1227849A2 (fr) | 2002-08-07 |
AU4906901A (en) | 2001-09-17 |
WO2001066155A3 (fr) | 2002-06-06 |
WO2001066155A2 (fr) | 2001-09-13 |
HUP0203743A2 (en) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6670456B2 (en) | Actinium-225 complexes and conjugates for targeted radiotherapy | |
US20020176818A1 (en) | High dose radionuclide complexes for bone marrow suppression | |
US7691985B2 (en) | Skeletal-targeted radiation to treat bone-associated pathologies | |
AU2002306598A1 (en) | Actinium-225 complexes and conjugates for targeted radiotherapy | |
JP2845328B2 (ja) | オルト結合官能性を有するキレート剤類およびそれらの錯塩類 | |
CA2381123C (fr) | Complexes et conjugat d'actinium-225 pour radio-immunotherapie | |
US8518715B2 (en) | Bifunctional polyazamacrocyclic chelating agents | |
AU650944B2 (en) | Method of treating and/or diagnosing soft tissue tumors | |
US20030086868A1 (en) | Actinium-225 complexes and conjugates for radioimmunotherapy | |
Bhalgat et al. | Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates | |
EP1438076B1 (fr) | Agent radiopharmaceutique pour le traitement du cancer a un stade precoce | |
AU2002353865A1 (en) | Radiopharmaceutical agent for the treatment of early stage cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20210223 |